Mr. Stephen Van Deventer reports

PREVECEUTICAL'S SUBSIDIARY, BIOGENE THERAPEUTICS, APPOINTS PRESIDENT

Preveceutical Medical Inc.'s wholly owned subsidiary, BioGene Therapeutics Inc., has appointed Dr. Mariya Georgieva as president, effective Nov. 11, 2024.

Stephen Van Deventer, chairman and chief executive officer of Preveceutical, commented: "I am extremely pleased to have Dr. Georgieva become part of BioGene as we advance our siRNA therapy in diabetes and obesity. Her strengths and talent will be extremely valuable to the company moving forward."

Dr. Georgieva is joining BioGene from AstraZeneca Ltd. in the United Kingdom, where she has been director, diagnostic alliances, within precision medicine R&D (research and development) since 2019. Prior to AstraZeneca, she was with ONI (Oxford Nanoimaging Ltd.), an Oxford-based start-up in the United Kingdom as head of applications and business development. Dr. Georgieva holds a PhD in biomedical science from the University of Montpellier (France), where she has developed single-molecule fluorescence tools to study the interplay between epigenetic alterations and the biophysical properties of chromatin during development.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene is a Texas-based life science company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D tax cashback incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.